Stocks and InvestingStocks and Investing
Tue, June 6, 2023
Mon, June 5, 2023
Sat, June 3, 2023
Fri, June 2, 2023

Keay Nakae Reiterated (ARWR) at Strong Buy and Held Target at $60 on, Jun 2nd, 2023


Published on 2024-10-28 04:10:06 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Reiterated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $60 on, Jun 2nd, 2023.

Keay has made no other calls on ARWR in the last 4 months.



There are 9 other peers that have a rating on ARWR. Out of the 9 peers that are also analyzing ARWR, 3 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Downgraded from Buy to Hold and Held Target at $40 on, Friday, May 12th, 2023
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $40 on, Wednesday, May 3rd, 2023
  • William Pickering of "Bernstein" Initiated at Hold and Held Target at $27 on, Tuesday, March 21st, 2023


These are the ratings of the 6 analyists that currently disagree with Keay


  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $60 on, Wednesday, May 3rd, 2023
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $73 on, Wednesday, May 3rd, 2023
  • David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $80 on, Wednesday, April 26th, 2023
  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Friday, February 10th, 2023
  • Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $55 on, Wednesday, February 8th, 2023
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $58 on, Tuesday, February 7th, 2023